Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.…
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
Protagonist Therapeutics (NASDAQ: PTGX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 149 employees.
The shares were at 121.40 USD on 20 November 2026, up 52.6% over 52 weeks. Its 52-week range is 77.00 USD to 160.81 USD: the price is 24.5% below the high and 57.7% above the low.
At a market capitalisation of 7.92B USD, it trades at 25.7 times trailing earnings and 348.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 23% for PTGX.
Protagonist Therapeutics reports return on equity of -21.2% and an operating margin of 58.6%.
It holds more cash than debt, a net cash position of 791.43M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 182.36 USD is 50.2% above the current price. The next earnings report is expected on 25 February 2027.